Literature DB >> 3278176

Chronic aortic regurgitation: indications for operation--1988.

R A Nishimura1, M D McGoon, H V Schaff, E R Giuliani.   

Abstract

Timing of operation in a patient with severe aortic regurgitation is a difficult and controversial decision, especially when the patient is asymptomatic or minimally symptomatic. A rational decision can be made when the pathophysiologic features of aortic regurgitation and the natural history of medically treated patients are understood and the benefits and risks associated with aortic valve replacement are known. Proper interpretation of the literature involving echocardiography and nuclear cardiology is essential, as is consideration of the constantly changing surgical techniques and results. Aortic valve replacement should be recommended for those patients with chronic aortic regurgitation who are severely symptomatic (New York Heart Association Functional Class III or IV), in order to ameliorate symptoms and increase longevity. In asymptomatic or minimally symptomatic patients, close continued serial follow-up is necessary in order to detect the onset of resting left ventricular dysfunction and to recommend the optimal timing for surgical intervention.

Entities:  

Mesh:

Year:  1988        PMID: 3278176     DOI: 10.1016/s0025-6196(12)65101-5

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Management of asymptomatic chronic aortic regurgitation with left ventricular dysfunction: a decision analysis.

Authors:  H J Biem; A S Detsky; P W Armstrong
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

2.  Decision making in the management of asymptomatic patients with aortic regurgitation: a cardiologist's perspective.

Authors:  C M Otto
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

Review 3.  Indications for surgery for aortic regurgitation.

Authors:  Vuyisile T Nkomo
Journal:  Curr Cardiol Rep       Date:  2003-03       Impact factor: 2.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.